Inclusion Criteria:

- Provision of written informed consent from the patient and their partner (if the
partner will be administering the lanreotide Autogel injections during the self
administration period)

- Male or female aged 18 years of age or older

- Treated with lanreotide Autogel 90 or 120 mg every 28th day for carcinoid symptoms on
a stable dose for at least 3 months prior to inclusion. The patient is presumed to be
clinically stable during the coming months

- Neuroendocrine tumour confirmed by biopsy and visible on radiology

Exclusion Criteria:

- Has a history of hypersensitivity to the Investigational Medicinal Product or drugs
with a similar chemical structure

- Has abnormal baseline findings, any other medical condition(s) or laboratory findings
that, in the opinion of the Investigator, might jeopardise the patient's safety or
decrease the chance of obtaining satisfactory data needed to achieve the objective(s)
of the study

- Has a life expectancy less than a year, as judged by the Investigator

- The patient or their partner is not considered competent in injection technique, as
judged by the Investigator